Importance:
The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.
Objective:
To study the neurologic manifestations of patients with COVID-19.
Design, Setting, And Participants:
This is a retrospective, observational case series. Data were collected from January 16, 2020, to February 19, 2020, at 3 designated special care centers for COVID-19 (Main District, West Branch, and Tumor Center) of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. The study included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection.
Main Outcomes And Measures:
Clinical data were extracted from electronic medical records, and data of all neurologic symptoms were checked by 2 trained neurologists. Neurologic manifestations fell into 3 categories: central nervous system manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscular injury manifestations.
Results:
Of 214 patients (mean [SD] age, 52.7 [15.5] years; 87 men [40.7%]) with COVID-19, 126 patients (58.9%) had nonsevere infection and 88 patients (41.1%) had severe infection according to their respiratory status. Overall, 78 patients (36.4%) had neurologic manifestations. Compared with patients with nonsevere infection, patients with severe infection were older, had more underlying disorders, especially hypertension, and showed fewer typical symptoms of COVID-19, such as fever and cough. Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 [2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]).
Conclusions And Relevance:
Patients with COVID-19 commonly have neurologic manifestations. During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.
Citing Articles
Rapid generation and characterization of recombinant HCoV-OC43-VR1558 infectious clones expressing reporter Renilla luciferase.
Ye F, Wang N, Guan Q, Wang M, Sun J, Zhai D
Biosaf Health. 2025; 6(6):350-360.
PMID: 40078980
PMC: 11894994.
DOI: 10.1016/j.bsheal.2024.11.006.
Nucleocapsid Protein of SARS-CoV-2 Upregulates RANTES Expression in A172 Glioblastoma Cells.
Gadilgereyeva B, Kunushpayeva Z, Abdrakhmanova M, Khassenova A, Minigulov N, Burster T
Molecules. 2025; 30(5).
PMID: 40076291
PMC: 11902235.
DOI: 10.3390/molecules30051066.
Prion propensity of Betacoronaviruses including SARS-CoV-2.
Haddad H, Al-Zyoud W
Heliyon. 2025; 11(4):e42199.
PMID: 40034268
PMC: 11874563.
DOI: 10.1016/j.heliyon.2025.e42199.
Editorial: NeuroCOVID. Insights into the clinical manifestations and pathophysiology.
Gonzalez-Quevedo A, Valdes Sosa P, Machado Curbelo C, Gutierrez Gil J
Front Neurol. 2025; 16:1561314.
PMID: 40007741
PMC: 11852433.
DOI: 10.3389/fneur.2025.1561314.
SARS-CoV-2: A synergy to the Alzheimer's disease.
Shaik K, Kumar D, Srikanth P, Nandi S
J Neurovirol. 2025; .
PMID: 39998800
DOI: 10.1007/s13365-025-01247-w.
Alcohol Consumption Modulates the Development of Chronic Pain in COVID-19 Patients: A Network Meta-Analysis.
Bishir M, Vigorito M, Chan M, Khan M, Chang S
ACS Pharmacol Transl Sci. 2025; 8(2):409-422.
PMID: 39974632
PMC: 11833718.
DOI: 10.1021/acsptsci.4c00479.
Identification of biomarkers in Alzheimer's disease and COVID-19 by bioinformatics combining single-cell data analysis and machine learning algorithms.
Li J, Tao L, Zhou Y, Zhu Y, Li C, Pan Y
PLoS One. 2025; 20(2):e0317915.
PMID: 39965013
PMC: 11835241.
DOI: 10.1371/journal.pone.0317915.
Neurologic features in hospitalized patients with COVID-19: a prospective cohort in a catalan hospital.
Barrachina-Esteve O, Anguita A, Reverter A, Espinosa J, Lafuente C, Rubio-Roy M
Neurol Sci. 2025; .
PMID: 39951175
DOI: 10.1007/s10072-025-08031-y.
The Role of Genetic, Environmental, and Dietary Factors in Alzheimer's Disease: A Narrative Review.
Mertas B, Bosgelmez I
Int J Mol Sci. 2025; 26(3).
PMID: 39940989
PMC: 11818526.
DOI: 10.3390/ijms26031222.
Differences in functional outcome of COVID-19 and non-COVID-19 patients with critical illness polyneuropathy/ myopathy: a multicenter cohort study.
Klein M, Einhaupl B, Grill E, Drunin G, Schmidt S, Cordes C
J Neurol. 2025; 272(3):197.
PMID: 39932563
DOI: 10.1007/s00415-024-12873-5.
Recanalization Outcomes and Procedural Complications in Patients With Acute Ischemic Stroke and COVID-19 Receiving Endovascular Treatment.
Marto J, Strambo D, Ntaios G, Nguyen T, Wrona P, Escalard S
J Stroke. 2025; 27(1):128-132.
PMID: 39916463
PMC: 11834345.
DOI: 10.5853/jos.2024.04077.
Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX).
Pupillo E, Bianchi E, Beghi E, Pedrazzini F, Giglio A, Schilke E
Sci Rep. 2025; 15(1):4179.
PMID: 39905221
PMC: 11794632.
DOI: 10.1038/s41598-025-88837-0.
CT scan-derived pectoralis muscle parameters are closely associated with COVID-19 outcomes: A systematic review and meta-analysis.
Wen Z, Wang T, Luo S, Liu Y
PLoS One. 2025; 20(1):e0316893.
PMID: 39874384
PMC: 11774355.
DOI: 10.1371/journal.pone.0316893.
Characterization of SARS-CoV-2 Entry Genes in Skeletal Muscle and Impacts of In Vitro Versus In Vivo Infection.
Bhattarai S, Kaufmann E, Liang F, Zheng Y, Gusev E, Hamid Q
J Cachexia Sarcopenia Muscle. 2025; 16(1):e13705.
PMID: 39871399
PMC: 11772215.
DOI: 10.1002/jcsm.13705.
Impact of the COVID-19 Pandemic on Seizure Control in Pediatric Epilepsy: Risk Factors and Clinical Outcomes.
Lim J, Moon J
Healthcare (Basel). 2025; 13(2).
PMID: 39857199
PMC: 11765434.
DOI: 10.3390/healthcare13020172.
Altered brain glucose metabolism in COVID-19 disease: an activation likelihood estimation meta-analysis of PET studies.
Kang D, Jung H, Pak K
Brain Imaging Behav. 2025; .
PMID: 39853627
DOI: 10.1007/s11682-025-00966-2.
Is There an Association between Bell Palsy in Pediatric Patients and COVID-19?.
El-Deeb M, Elzayat S, Salamah A, Gamal A, Elgamal S, El-Sobki A
Int Arch Otorhinolaryngol. 2025; 29(1):1-8.
PMID: 39850499
PMC: 11756956.
DOI: 10.1055/s-0044-1789197.
Possible mechanisms of spermatogenic dysfunction induced by viral infections: Insights from COVID-19.
Okada K, Kin C, Yamashita Y, Kawamura S, Sato K, Chiba K
Reprod Med Biol. 2025; 24(1):e12625.
PMID: 39845480
PMC: 11751869.
DOI: 10.1002/rmb2.12625.
Alzheimer's disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles.
Hosseininasab S, Ebrahimi R, Yaghoobpoor S, Kazemi K, Khakpour Y, Hajibeygi R
Front Neurosci. 2025; 18():1513095.
PMID: 39840010
PMC: 11747386.
DOI: 10.3389/fnins.2024.1513095.
COVID-19-Associated Encephalopathy: A Case Series Demonstrating the Rapid Deterioration of Mental Status and a Review of the Literature.
Reny J, Siddiqui U, Cox A, Hennawi H, Swanson J, Siegel A
Cureus. 2025; 16(12):e76005.
PMID: 39834950
PMC: 11743337.
DOI: 10.7759/cureus.76005.